The United States **Food and Drug Administration (FDA)** has issued a third **Complete Response Letter (CRL)** to **Hengrui Pharmaceuticals** and its partner **Elevar Therapeutics** regarding their application for **rivoceranib** in combination with **camrelizumab** for the treatment of **unresectable hepatocellular carcinoma (HCC)**, the most common form of liver cancer. This latest regulatory hurdle marks a significant setback for the companies, as they had sought approval for the drug combination as a first-line treatment for patients with advanced disease.
Details surrounding the specific reasoning for the latest rejection have not been fully disclosed, but past regulatory reviews have highlighted concerns regarding clinical trial site inspections and data integrity. The ongoing inability to secure approval for this **tyrosine kinase inhibitor** and **PD-1 inhibitor** regimen underscores the rigorous standards the agency maintains regarding the evidence supporting new oncology therapies in the United States.
While one major drug candidate faces continued scrutiny, **GSK** is moving forward with aggressive regulatory plans for its own oncology portfolio. The pharmaceutical giant has announced intentions to seek **FDA approval** for **Jemperli (dostarlimab)**—a **monoclonal antibody** that functions as a **programmed death receptor-1 (PD-1) blocking antibody**—as a potential treatment for **dMMR/MSI-H locally advanced rectal cancer**.
**Jemperli** has already gained significant attention in the medical community following data suggesting it could potentially eliminate the need for traditional surgery, chemotherapy, or radiation in specific subsets of patients with mismatch repair-deficient rectal tumors. By targeting these specific genetic markers, **GSK** hopes to offer a revolutionary, organ-sparing therapeutic option for a population that currently faces highly invasive treatment regimens.
The divergence in these two regulatory paths highlights the high-stakes nature of the current oncology landscape. While the path for **rivoceranib** remains stalled due to persistent safety or efficacy documentation requirements, the push for **Jemperli** demonstrates a shift toward precision medicine where molecular profiling plays a central role in therapeutic indication.
Industry experts are closely monitoring both developments. For liver cancer patients, the rejection of the **Hengrui-Elevar** combination limits the availability of new first-line treatment alternatives. Conversely, the potential expansion of **Jemperli’s** label could set a new standard of care for rectal cancer patients, shifting the focus from radical surgical intervention to immunotherapy-led remission strategies. Further updates from both manufacturers are expected in the coming quarters as they navigate these complex regulatory landscapes.
